Leveragen

Leveragen specializes in developing innovative genetic models for antibody discovery and other therapeutic applications. They specialize in creating designer mutations in embryonic stem (ES) cells using CRISPR-facilitated gene targeting technology. This allows for screening of designed mutations before developing knockout mice, making it suitable for complex modifications. Their flagship platform, Singularity Sapiens Mouse, leverages CRISPR to generate mice that exclusively produce human heavy chain antibodies. By utilizing the Singularity Sapiens Mouse, Leveragen also facilitates rapid screening of a vast repertoire of human antibody sequences for potential therapeutic candidates. The platform generates human single-domain antibodies, known for their smaller size, better tissue penetration, and potentially lower immunogenicity compared to traditional antibodies. Leveragen offers researchers and pharmaceutical companies a tailored approach to antibody discovery, allowing them to target specific antigens of interest.

Jobs: